Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals
Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
FAST NEWS: Legend Biotech shares jump on rising cancer drug sales
LEGN.US
-
FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales
LEGN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter